Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer

Abstract

Low-dose dexamethasone has significant activity in CRPC. Subject to validation with more clinically meaningful endpoints, dexamethasone could become the corticosteroid of choice in the management of CRPC, and its potential for use in combination with novel agents should be explored.